BUZZ-Biofrontera's US-listed shares fall as Q3 revenue misses estimates

Reuters11-15

** U.S.-listed shares of Biofrontera Inc fall 11% to 74 cents

** On Wednesday, company reported Q3 rev. of $9 mln, missing two analysts' average est. of $10 mln, due to disruption from hurricanes

** Q3 loss of 98 cents/shr wider than est. loss of 84 cents/shr, according to data compiled by LSEG

** BFRI likely to report strong Q4 revenue, as demand for Ameluz, company's treatment for a type of skin condition, increases in less-sunny weather - Brokerage Roth MKM

** Company to also benefit from Ameluz price hike of October and hurricane-interrupted sales moving into the quarter - Roth MKM

** Including session gains, BFRI down 73.5% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment